UNSPSC 51312808: Mequitamium iodide

This classification denotes a histamine-1 receptor antagonist and antimuscarinic agent with the molecular formula C21H25N2S.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50D69ZKZ7M, chemically known as 1-azoniabicyclo(2.2.2)octane, 1-methyl-3-(10h-phenothiazin-10-ylmethyl)-, iodide but generally known as mequitamium iodide, which bears US NIH Compound Identifier 72028. European Medicines Agency schedules Mequitamium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08765MIG.

UNSPSC 51312808 Mequitamium iodide is a Commodity code that does not reflect the actual pharmaceutical and health-supply acquisitions currently posted under it by state and local buyers. The recent opportunities tagged to this code show state and local governments purchasing naloxone and drug deactivation systems, generic multi-source pharmaceuticals with over-the-counter products through cooperative purchasing arrangements, and conducting market research on direct-to-manufacturer prescription programs — none of which align with mequitamium iodide itself. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances, with work ranging from annual competitive bids for emergency-response supplies to RFPs establishing statewide pharmaceutical distribution contracts and preliminary RFIs informing future procurement strategy.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023; the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code shows little relevant recent activity aligned to its nominal definition; the mismatch between the code label and actual procurement scope signals that this taxonomy entry may be misconfigured or that the issuing bodies are applying it inconsistently to broader pharmaceutical and health-supply categories.